Implicity
Remote monitoring of cardiac implantable electronic devices (CIEDs) generates large volumes of data, including false alerts and disconnected patients, which can overwhelm care teams and delay clinical responses.
Public-source profile · Company ownership not verified. Sources & corrections
The short feature · 2 min read
Implicity, at a glance
Built for · Cardiologists, cardiac care teams, hospital administrators, and billing staff involved in remote monitoring of patients with CIEDs such as pacemakers, ICDs,…
Based on company material. Product claims are attributed to the company.
- 01
The problem
Conventional remote monitoring of CIEDs produces excessive false alerts and disconnected patients, leading to inefficiencies in care delivery. For example, 28% of patients may disconnect from monitoring, and false positives in ILR ECG analysis can require unnecessary review of episodes.
Sources [1]
- 02
The product approach
Implicity’s platform centralizes data from multiple CIED manufacturers into a single system and applies FDA-cleared AI algorithms to filter alerts and highlight clinically relevant events. The platform automates workflows such as patient reconnection via SMS, billing compliance, and report generation, aiming to reduce manual review time and improve response efficiency.
Sources [1]
- 03
What stands out
, Abbott, Biotronik, Boston Scientific, Medtronic) into one interface. The platform’s AI-driven alert management is designed to reduce unnecessary alerts—such as an 85% decrease in atrial fibrillation (AF) alerts compared to standard CIED transmissions—and includes predictive tools like SignalHF for hospitalization risk.
Sources [1]
What could be hard to replicate?
A useful product is not automatically a moat. These mechanisms need evidence of a lasting advantage.
Technology & IP
Company claimImplicity’s platform is built on FDA-cleared AI algorithms for ECG analysis and alert filtering, which are validated as medical devices. These include ILR ECG Analyzer (reducing false positives by 79% while maintaining 99% sensitivity) and AF Alert Management (reducing unnecessary AF alerts by 85%).
Mechanism → evidence check
What prevents another team from reproducing the capability?
Sources [1]
Switching costs
Company claimThe platform’s ability to integrate data from multiple CIED manufacturers into a standardized system may create a switching cost for care teams. Clinics using Implicity would need to adapt workflows to a single interface rather than managing separate manufacturer portals.
Mechanism → evidence check
What value would a customer lose when changing products?
Sources [1]
The question to watch
What evidence shows that customers choose this product over alternatives, and keep using it?
Explore the evidence · 1 source
- [1] Implicity company website
Company material · checked 5/10/2026
Volume 42, Issue Supplement_1, October 2021. 7 Durand, Julien, et al., Using Technology to Improve Reconnection to Remote Monitoring in Cardiac Implantable Electronic Device Patients,…
About
At Implicity, we help improve the patient care standard by offering an effective AI-based remote monitoring solution
Founders
- Dr. Arnaud Rosier
Profile sources, ownership & corrections
Company ownership is not verified
This profile was compiled from public sources and hasn't been verified by Implicity. Claim it to correct the details, add your team and funding history, and request review of your company information.
Compiled from news coverage, the company's own website.
Similar startups
AI3D Studio — ai3d.studio
AI3D Studio is a browser-based platform that converts 2D inputs—such as photos, text prompts, sketches.
SignSplit is a platform designed to allow individuals and institutions to manage their data, work, and likeness by enabling protection, licensing.
Decart is an AI lab developing real-time world models designed to operate at millisecond latency.
Isomorphic Labs is a company applying artificial intelligence to drug discovery.